Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
| ▸ | ADORA2B | P29275 | 1/20 | 0.30 |
| ▸ | BLM | P54132 | 1/20 | 0.30 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13970127 | 1.00 | KDM4E (0.33) | KDM4ELMNARAB9ASMN1; SMN2GLA | |
| SCHEMBL12748527 | 0.88 | LMNA (0.31) | LMNARAB9ASMN1; SMN2GLAADORA2B | |
| SCHEMBL12749037 | 0.72 | — | — | |
| SCHEMBL13970114 | 0.72 | TYMP (0.41) | LMNASMN1; SMN2BLMALDH1A1MAPK1 | |
| SCHEMBL12748997 | 0.69 | GRIN1 (0.31) | — | |
| SCHEMBL13970113 | 0.66 | — | — | |
| SCHEMBL24548479 | 0.61 | TYMP (0.42) | LMNASMN1; SMN2BLMALDH1A1MAPK1 | |
| SCHEMBL6555940 | 0.58 | TYMP (0.42) | LMNASMN1; SMN2BLMALDH1A1MAPK1 | |
| SCHEMBL1902451 | 0.58 | TYMP (0.42) | LMNASMN1; SMN2BLMALDH1A1MAPK1 | |
| SCHEMBL12748530 | 0.58 | TYMP (0.42) | LMNASMN1; SMN2BLMALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7928210-B2 | Nucleoside based proliferation imaging markers | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-20090016958-A1 | Nucleoside based proliferation imaging markers | SIEMENS MEDICAL SOLUTIONS USA, INC. | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090016958-A1 | Nucleoside based proliferation imaging markers | MKI67, SLC29A1, SLC29A2 | KDM4E 4684/4885LMNA 999/4885RAB9A 2453/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.